Showing 7381-7390 of 7643 results for "".
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33
- Merz Appoints New Vice President of Medical Dermatologyhttps://practicaldermatology.com/news/20120611-merz_appoints_new_vice_president_of_medical_dermatology/2459786/Merz, Inc. has appointed James P. Hartman as Vice President of Medical Dermatology. In the new role, Hartman will be responsible for the company's Medical and OTC/OTX dermatology business unit, which includes Naftin® (naftifine hydrochloride) and Mede
- EWG Releases 2012 Sunscreen Guide and Apphttps://practicaldermatology.com/news/20120608-ewg_releases_2012_sunscreen_guide_and_app/2459787/After rating 257 brands and more than 1,800 products, the Environmental Working Group (EWG) released its sixth annual Guide to Summer Sun. EWG recommends 1 in 4 of more than 800 beach and sport sunscreens, compared to 1 in 5 l
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- FotoFinder Unveils New Imaging Technologieshttps://practicaldermatology.com/news/20120604-fotofinder_unveils_new_imaging_technologies/2459790/FotoFinder presented new devices for early skin cancer detection at the World Congress of Dermoscopy in Brisbane last month. Among new developments is the connection of a mobile dermatoscope for iPhone with an online webspace where doctors can requ
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared w
- New Isotretinoin Formulation Approvedhttps://practicaldermatology.com/news/20120529-new_isotretinoin_formulation_approved/2459794/A novel isotretinoin formulation for the treatment of severe recalcitrant nodular acne will soon be available from Ranbaxy. FDA approved Absorica (cis-isotretinoin), which
- Merz Realignment Focuses on Synergieshttps://practicaldermatology.com/news/20120518-merz_realignment_focuses_on_synergies/2459796/Merz is realigning and integrating its core businesses in the United States and Canada into one organization, with a single leadership team, the company announced. According to Merz, "the newly aligned structure is designed to stre
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- New Retinoid Foam Wins FDA Approvalhttps://practicaldermatology.com/news/20120514-new_retinoid_foam_wins_fda_approval/2459805/The FDA has approved Fabior (tazarotene) Foam, 0.1%, for the treatment of acne vulgaris in patients 12 years and older. The approval was based on two multi-center, randomized, double-blind, vehicle-controlled pivotal Phase 3 studies, in which a total of 1,485 patients with moderate-to-severe acne vu